Session Details

[2-JS1]Japan–Thailand Pharmacological Joint Symposium

Tue. Mar 17, 2026 2:10 PM - 4:10 PM JST
Tue. Mar 17, 2026 5:10 AM - 7:10 AM UTC
Room 3(B200)
Chair:Shuhei Tomita(Osaka Metropolitan University), Panich Uraiwan(Faculty of Medicine Siriraj Hospital, Mahidol University)
Commentator: Yasuhito Uezono (Dept. Pain Ctrl., Grad. Sch. Med., Tokyo Jikei Univ.)
This Japan-Thailand joint symposium will highlight recent advances in pharmacological and drug discovery research addressing cellular stress responses and therapeutic innovation, with a particular focus on cancer and related pathologies. The session will explore how pharmacological interventions modulate adaptive mechanisms such as hypoxia, inflammation, and epithelial remodeling, all of which critically influence disease progression, treatment response, and clinical outcomes.
The symposium will also address key pharmacological challenges in cancer, with particular attention to pain-related neural signaling, symptom management, and emerging insights from cancer neuroscience that emphasize active crosstalk between the nervous system and tumor progression. By integrating perspectives from basic pharmacology, drug discovery, and clinically relevant research, the session aims to provide a coherent view of cancer pharmacology spanning molecular mechanisms to patient-centered care.

[2-JS1-05]Pharmacologic Modulation of Mitochondrial Signaling and KC–FB Crosstalk in UVB-Induced Skin Damage

*Panich Uraiwan1 (1. Faculty of Medicine Siriraj Hospital, Mahidol University)
Comment()

[2-JS1-06]A possible new direction to target cancer: alteration of chromatin structure in hypoxic tumor microenvironment

*Koh Nakayama1 (1. Asahikawa Medical University)
Comment()

[2-JS1-07]Precision Design for Stemness Control: Navigating SAR Pathways to Disrupt Cancer Tissue Homeostasis

*Pithi Chanvorachote1 (1. Chulalongkorn University)
Comment()

[2-JS1-08]Sensory neuron-mediated regulation of tumor progression: Neuropeptide-dependent counter-regulation

*Minoru Narita1,2, Hitoshi Makabe1,2, Naoko Kuzumaki1,2 (1. Dept. Pharmacol., Hoshi Univ., 2. Lab. Cancer Pathophysiol., Natl. Cancer Ctr. Res. Inst.)
Comment()